Puma Biotechnology, Inc.

Release Summary

Puma Biotechnology announced interim 5-year disease free survival data from its Phase III Trial of PB272 (Neratinib) in extended adjuvant HER2-positive early stage breast cancer (ExteNET Trial).

Puma Biotechnology, Inc.